1. Home
  2. IART vs ABUS Comparison

IART vs ABUS Comparison

Compare IART & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Integra LifeSciences Holdings Corporation

IART

Integra LifeSciences Holdings Corporation

HOLD

Current Price

$15.11

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.37

Market Cap

848.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IART
ABUS
Founded
1989
2005
Country
United States
United States
Employees
4427
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
848.8M
IPO Year
1996
2008

Fundamental Metrics

Financial Performance
Metric
IART
ABUS
Price
$15.11
$4.37
Analyst Decision
Hold
Strong Buy
Analyst Count
7
1
Target Price
$14.33
$5.00
AVG Volume (30 Days)
1.1M
1.7M
Earning Date
05-05-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
55.26
EPS
N/A
0.87
Revenue
N/A
$14,083,000.00
Revenue This Year
$4.39
N/A
Revenue Next Year
$3.40
$239.71
P/E Ratio
N/A
$5.10
Revenue Growth
N/A
128.21
52 Week Low
$8.70
$3.04
52 Week High
$16.42
$5.10

Technical Indicators

Market Signals
Indicator
IART
ABUS
Relative Strength Index (RSI) 70.06 50.92
Support Level $12.64 $4.17
Resistance Level $16.35 $4.60
Average True Range (ATR) 0.91 0.16
MACD 0.11 0.01
Stochastic Oscillator 90.11 61.46

Price Performance

Historical Comparison
IART
ABUS

About IART Integra LifeSciences Holdings Corporation

Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: